The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wang, Xiaoyi ^a   Xiong, Weiliang ^a   Ma, Xiaochu ^a   Wei, Meili ^a   Chen, Yanxia ^a   Lu, Lu ^b,c   Debnath, Asim K ^c   Jiang, Shibo ^b,c   Pan, Chungen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; SODIUM CHLORIDE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CELL FUSION; CONSERVATION BIOLOGY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR STABILITY; NONHUMAN; PROTEIN FUNCTION; RESIDUE ANALYSIS; SURFACE CHARGE; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY;

AMINO ACID SEQUENCE; ARGININE; CIRCULAR DICHROISM; HIV ENVELOPE PROTEIN GP41; HUMANS; HYDROGEN PEROXIDE; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; REPETITIVE SEQUENCES, AMINO ACID; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866113593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044874     Document Type: Article

References (37)

1. Freed EO, Martin MA, (1995) The role of human-immunodeficiency virus type-1 envelope glycoproeins in viurs-inection. J Biol Chem 270: 23883-23886.
2. Eckert DM, Kim PS, (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
3. Esser MT, Mori T, Mondor I, Sattentau QJ, Dey B, et al. (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 73: 4360-4371.
4. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280: 1884-1888.
5. Chan DC, Fass D, Berger JM, Kim PS, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
6. Jiang S, Lin K, Strick N, Neurath AR, (1993) HIV-1 inhibition by a peptide. Nature 365: 113.
7. Chan DC, Kim PS, (1998) HIV entry and its inhibition. Cell 93: 681-684.
8. Dimitrov DS, (1997) How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell 91: 721-730.
9. Feng Y, Broder CC, Kennedy PE, Berger EA, (1996) HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.
10. Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, et al. (2005) Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 102: 12903-12908.
11. Gochin M, Cai L, (2009) The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. J Med Chem 52: 4338-4344.
12. Follis KE, Larson SJ, Lu M, Nunberg JH, (2002) Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J Virol 76: 7356-7362.
13. Cao J, Bergeron L, Helseth E, Thali M, Repke H, et al. (1993) Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 67: 2747-2755.
14. Lu M, Stoller MO, Wang S, Liu J, Fagan MB, et al. (2001) Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol 75: 11146-11156.
15. Weng Y, Yang Z, Weiss CD, (2000) Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 74: 5368-5372.
16. Weng Y, Weiss CD, (1998) Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 72: 9676-9682.
17. Wang S, York J, Shu W, Stoller MO, Nunberg JH, et al. (2002) Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. Biochemistry 41: 7283-7292.
18. Ji H, Shu W, Burling FT, Jiang S, Lu M, (1999) Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 73: 8578-8586.
19. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185.
20. Dai SJ, Dou GF, Qiang XH, Song HF, Tang ZM, et al. (2005) Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 26: 1274-1280.
21. Suntoke TR, Chan DC, (2005) The fusion activity of HIV-1 gp41 depends on interhelical interactions. J Biol Chem 280: 19852-19857.
22. Shu W, Liu J, Ji H, Radigen L, Jiang S, et al. (2000) Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39: 1634-1642.
23. Tan K, Liu J, Wang J, Shen S, Lu M, (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94: 12303-12308.
24. Weissenhorn W, Calder LJ, Dessen A, Laue T, Skehel JJ, et al. (1997) Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. Proc Natl Acad Sci U S A 94: 6065-6069.
25. Malashkevich VN, Chan DC, Chutkowski CT, Kim PS, (1998) Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A 95: 9134-9139.
26. Sen J, Yan T, Wang J, Rong L, Tao L, et al. (2010) Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry 49: 5057-5065.
27. Liu J, Shu W, Fagan MB, Nunberg JH, Lu M, (2001) Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: Implications for membrane fusion. Biochemistry 40: 2797-2807.
28. Chang DK, Cheng SF, Yang SH, (2000) A helix initiation motif, XLLRA, is stabilized by hydrogen bond, hydrophobic and van der Waals interactions. Biochim Biophys Acta 1478: 39-50.
29. MOE (2010) Chemical Computing Group, Inc. Montreal, Quebec, Canada version 2010.
30. He Y, Liu S, Jing W, Lu H, Cai D, et al. (2007) Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem 282: 25631-25639.
31. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC, (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
32. Edelhoch H, (1967) Spectrocopic determination of tryptophan and tryosine in proteins. Biochemistry 6: 1948-1954.
33. Liu S, Lu H, Niu J, Xu Y, Wu S, et al. (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280: 11259-11273.
34. Liu S, Jing W, Cheung B, Lu H, Sun J, et al. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 282: 9612-9620.
35. Jiang S, Lu H, Liu S, Zhao Q, He Y, et al. (2004) N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 48: 4349-4359.
36. Pan C, Cai L, Lu H, Qi Z, Jiang S, (2009) Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and-resistant HIV type 1 strains. J Virol 83: 7862-7872.
37. He Y, D'Agostino P, Pinter A, (2003) Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine 21: 4421-4429.